Baricitinib , ≥99% , 1187594-09-7

CAS NO.：1187594-09-7

Empirical Formula: C16H17N7O2S

Molecular Weight: 371.42

MDL number: MFCD21608464

EINECS: 691-421-4

PRODUCT Properties

• Melting point: 212-215°C
• Density: 1.56
• storage temp.: -20°C
• solubility: Soluble in DMSO (up to 30 mg/ml) or in DMF (up to 50 mg/ml).
• pka: 11.66±0.50(Predicted)
• form: solid
• color: White or off-white
• Stability: Stable for 2 years from date of purchase as supplied. Solutions in DMSO or DMF may be stored at -20°C for up to 3 months.
• InChI: InChI=1S/C16H17N7O2S/c1-2-26(24,25)22-9-16(10-22,4-5-17)23-8-12(7-21-23)14-13-3-6-18-15(13)20-11-19-14/h3,6-8,11H,2,4,9-10H2,1H3,(H,18,19,20)
• InChIKey: XUZMWHLSFXCVMG-UHFFFAOYSA-N
• SMILES: N1(S(CC)(=O)=O)CC(N2C=C(C3N=CN=C4NC=CC4=3)C=N2)(CC#N)C1

Description and Uses

Baricitinib (1187594-09-7), approved by the FDA for two inflammatory disorders, rheumatoid arthritis and alopecia areata, selectively inhibits Janus kinase 1 (IC50?= 5.9 nM) and 2 (5.7 nM), over 3 (0.56 μM).1?It thereby blocks JAK/STAT signaling, reducing cytokine release and suppressing the innate and adaptive immune systems.1,2?Was recently shown to significantly improve COVID-19 symptoms in a preliminary human trial, presumably through suppression of the cytokine release syndrome (“cytokine storm”) induced by SARS-CoV-2 infection.3

Baricitinib is a JAK1 and JAK2 inhibitor and have been used as a promising treatment for rheumatoid arthritis.

Safety

• Symbol(GHS): GHS07
• Signal word: Warning
• Hazard statements: H302
• Precautionary statements: P280-P305+P351+P338
• HS Code: 29350090